Pharmaceuticals company AstraZeneca Pharma India announced Q1FY26 results Revenue from Operations: Rs 5263.1 million compared to Rs 3,875.2 million during Q1FY25. PBT: Rs 750.6 million compared to Rs 424.0 million during Q1FY25. PAT: Rs 558.3 million compared to Rs -117.9 million during Q1FY25. Bhavana Agrawal, Chief Financial Officer & Director, said: “Our strong Q1 performance reflects the power of science-led innovation combined with disciplined execution. Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases. We remain focused on expanding our portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most.” Praveen Rao Akkinepally, Country President & Managing Director, said: “Delivering consistent growth across therapy areas reaffirms the strength of our Growth Through Innovation strategy and the passion of our teams to help more patients. At AstraZeneca, we are guided by a bold ambition to transform patient outcomes by delivering the right treatment at the right time. These results are a testament to what is possible when science and purpose come together.” Result PDF